NasdaqGS - Nasdaq Real Time Price USD

Bio-Techne Corporation (TECH)

Compare

75.19

+0.42

(+0.56%)

At close: January 8 at 4:00:01 PM EST

76.56

+1.37

(+1.82%)

Pre-Market: 6:05:52 AM EST

ScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's Therapeutics

ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, today announced that Seattle Children's Therapeutics, a division of the Seattle Children's Research Institute has been awarded a $125,000 G-Rex Grant. The G-Rex Grant will integrate state-of-the-art advancements into Seattle Children's Therapeutics' G-Rex based CAR-T cell platform.

PR Newswire yesterday

TECH
+0.56%
BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025

Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas.

PR Newswire yesterday

TECH
+0.56%
BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC

Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.

PR Newswire 2 days ago

TECH
+0.56%
Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?

TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes.

Zacks 17 days ago

TECH
+0.56%
WAT
-0.75%
HAE
BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

PR Newswire 20 days ago

TECH
+0.56%
BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT

Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS System from Waters) to deliver i

PR Newswire 21 days ago

TECH
+0.56%
ScaleReady awards a G-Rex® Grant to Moonlight Bio

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell therapy for the treatment of solid tumors.

PR Newswire 22 days ago

TECH
+0.56%
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?

TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay.

Zacks 28 days ago

TECH
+0.56%
HAE
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY

Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen brands across Turkey.

PR Newswire 28 days ago

TECH
+0.56%
BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY

Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The research-use-only assay, which consists of a qPCR detection kit as well as an isolation kit for cell-free DNA and exosomal RNA, will be featured in the Asuragen booth (#1429) at the San Antonio Breast Cancer Symposium beginning on December 10t

PR Newswire 30 days ago

TECH
+0.56%
Can Mixed Financials Have A Negative Impact on Bio-Techne Corporation's 's (NASDAQ:TECH) Current Price Momentum?

Bio-Techne's (NASDAQ:TECH) stock is up by 5.5% over the past three months. However, the company's financials look a bit...

Simply Wall St. last month

TECH
+0.56%
Should You Continue to Retain Bio-Techne Stock in Your Portfolio?

Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.

Zacks last month

TECH
+0.56%
HAE

BSX
Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

TECH
+0.56%
EXEL
BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE

Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

PR Newswire last month

TECH
+0.56%
Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne

Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH).

PR Newswire last month

TECH
+0.56%
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES

Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.

PR Newswire last month

TECH
+0.56%
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH

Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

PR Newswire last month

TECH
+0.56%
BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO

Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811.

PR Newswire last month

TECH
+0.56%
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS

Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices.

PR Newswire last month

TECH
+0.56%
BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS

Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices.

PR Newswire last month

TECH
+0.56%

Performance Overview

Return	TECH	S&P 500
YTD	+4.01%	+0.19%
1-Year	+6.22%	+25.99%
3-Year	-26.69%	+26.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bio-Techne Corporation (TECH)

ScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's Therapeutics

BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025

BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC

Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?

BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT

ScaleReady awards a G-Rex® Grant to Moonlight Bio

Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?

BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY

BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY

Can Mixed Financials Have A Negative Impact on Bio-Techne Corporation's 's (NASDAQ:TECH) Current Price Momentum?

Should You Continue to Retain Bio-Techne Stock in Your Portfolio?

Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?

BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE

Gemini Bioproducts, LLC Acquires Selected Fetal Bovine Serum (FBS) Product Rights and Inventory from Bio-Techne

BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES

BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH

BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO

UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS

BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS

Performance Overview